The long intergenic noncoding RNA GAS5 reduces cisplatin-resistance in non-small cell lung cancer through the miR-217/LHPP axis.
Long noncoding RNAs (lncRNAs) are known to exert their effects to tumor progression. In this study, the role of the lncRNA GAS5 (growth arrest specific 5) was confirmed in reducing non-small cell lung cancer (NSCLC) cisplatin (DDP) resistance. In NSCLC tissue samples, GAS5 expression decreased significantly. Low GAS5 levels were positively correlated with NSCLC characteristics including TNM, tumor size and lymphatic metastasis. Functionally, GAS5 significantly reduced NSCLC/DDP cell migration, invasion and epithelial-mesenchymal transition (EMT) progression in vitro. In vivo, GAS5 upregulation inhibited remarkably NSCLC/DDP cell tumor growth. Mechanism analysis suggested that GAS5 was a molecular sponge of miR-217, inhibiting the expression of phospholysine phosphohistidine inorganic pyrophosphate phosphatase (LHPP). In conclusion, this study reveals that the GAS5/miR-217/LHPP pathway reduces NSCLC cisplatin resistance and that LHPP may serve as a potential therapeutic target for NSCLC cisplatin resistance.
['Yang|Xuhui|X|', 'Meng|Lifei|L|', 'Zhong|Yuang|Y|', 'Hu|Fengqing|F|', 'Wang|Lei|L|', 'Wang|Mingsong|M|']
D000818:Animals D000970:Antineoplastic Agents D002289:Carcinoma, Non-Small-Cell Lung D045744:Cell Line, Tumor D049109:Cell Proliferation D002945:Cisplatin D019008:Drug Resistance, Neoplasm D058750:Epithelial-Mesenchymal Transition D005260:Female D015972:Gene Expression Regulation, Neoplastic D006801:Humans D043564:Inorganic Pyrophosphatase D008175:Lung Neoplasms D008297:Male D051379:Mice D035683:MicroRNAs D008875:Middle Aged D062085:RNA, Long Noncoding D015398:Signal Transduction D023041:Xenograft Model Antitumor Assays
non-small cell lung cancer miR-217 LHPP